Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51

Fig. 6

Metformin enhances cisplatin-induced DNA damage. a, b Western blotting analyses of phospho-Ser139 H2AX expression in Hs 578T and MDA-MB-231 cells treated with cisplatin, metformin, or their combination. a Cells were exposed to cisplatin (0.5~10 μM) for 6 h. b Cells were treated with metformin (5 mM) and cisplatin (5 μM), either alone or in combination, for 6 h. c Immunofluorescence staining of Hs 578T and MDA-MB-231 cells after treatment with metformin (5 mM) and cisplatin (5 μM), either alone or in combination, for 24 h. Cells were immunostained with antibodies against γ-H2AX (Ser139) (red) and RAD51 (green), as well as with Hoechst 33342 (blue; nucleus). Scale bars = 20 μm. Results represent the mean ± SEM of five independent experiments. #, ##, ## vs. no treatment; #P < 0.05, ##P < 0.01, ###P < 0.001, *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA followed by Bonferroni’s post hoc test

Back to article page